^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) + Darzalex (daratumumab) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/12/2021
Excerpt:
Therapy for previously treated Multiple Myeloma…Other recommended regimens…selinexor/daratumumab/dexamethasone
